Peroxisome proliferator-activated receptor gamma mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells.
Insulin resistance and diabetes mellitus promote the atherosclerotic process, where an endothelial dysfunction plays a key role. The diabetic milieu elevates the production of the plasminogen activator inhibitor type 1 (PAI-1) and also increases the proliferation of vascular endothelial cells. Recently the role of peroxisome proliferator-activated receptor gamma (PPARgamma) in atherosclerosis has been extensively studied. However, the direct effect of PPARgamma in vascular endothelial cells is still unclear. Therefore, the effect of PPARgamma was investigated to determine if it plays an important role in PAI-1 production and cellular proliferation in human umbilical vein endothelial cells (HUVEC). A combination of PPARgamma-overexpression and troglitazone treatment (5 ug/ml) significantly decreased both the PAI-1 mRNA and protein expression, while PPARgamma-overexpression or troglitazone alone tended to decrease both the PAI-1 protein and mRNA expression. PPARgamma-overexpression or troglitazone treatment alone reduced the thymidine uptake by the HUVEC with or without TNFalpha treatment. There was a further decrease in the thymidine uptake with troglitazone treatment in the PPARgamma-overexpressed HUVEC. In conclusion, PPARgamma can reduce PAI-1 production in HUVEC directly by transcriptional repression, and may play a beneficial role in preventing cardiovascular events. PPARgamma can also inhibit vascular endothelial cell proliferation, and its clinical relevance in diabetic vascular complications should be elucidated.
Hong
Hye Kyung
HK
Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-Dong Chongno-Gu, Seoul 110-744, South Korea.
Cho
Young Min
YM
Park
Kyung-Ho
KH
Lee
Choon Taek
CT
Lee
Hong Kyu
HK
Park
Kyong Soo
KS
D002455:Cell Division / Q000187:drug effects*; D002478:Cells, Cultured; D002839:Chromans / Q000494:pharmacology; D003001:Cloning, Molecular; D004730:Endothelium, Vascular / Q000166:cytology* / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007231:Infant, Newborn; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics; D011994:Recombinant Proteins / Q000494:pharmacology; D015183:Restriction Mapping; D045162:Thiazolidinediones / Q000494:pharmacology; D014157:Transcription Factors / Q000235:genetics / Q000494:pharmacology*; D014158:Transcription, Genetic / Q000187:drug effects / Q000235:genetics; D000077288:Troglitazone; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014471:Umbilical Veins
D002839:Chromans; D007004:Hypoglycemic Agents; D017395:Plasminogen Activator Inhibitor 1; D012333:RNA, Messenger; D018160:Receptors, Cytoplasmic and Nuclear; D011994:Recombinant Proteins; D045162:Thiazolidinediones; D014157:Transcription Factors; D014409:Tumor Necrosis Factor-alpha; D000077288:Troglitazone